nodes	percent_of_prediction	percent_of_DWPC	metapath
Danazol—Pigmentation skin—Methimazole—Graves' disease	0.121	0.182	CcSEcCtD
Danazol—Pigmentation skin—Propylthiouracil—Graves' disease	0.103	0.155	CcSEcCtD
Danazol—Pigmentation disorder—Methimazole—Graves' disease	0.0662	0.0995	CcSEcCtD
Danazol—Pigmentation disorder—Propylthiouracil—Graves' disease	0.0563	0.0846	CcSEcCtD
Danazol—Interstitial pneumonia—Propylthiouracil—Graves' disease	0.0389	0.0584	CcSEcCtD
Danazol—Interstitial lung disease—Propylthiouracil—Graves' disease	0.0266	0.0399	CcSEcCtD
Danazol—GNRHR—Hormone ligand-binding receptors—TSHR—Graves' disease	0.0264	0.18	CbGpPWpGaD
Danazol—CCL2—eye—Graves' disease	0.0155	0.0825	CbGeAlD
Danazol—CCL2—connective tissue—Graves' disease	0.0149	0.0795	CbGeAlD
Danazol—GNRHR—pituitary gland—Graves' disease	0.0147	0.0784	CbGeAlD
Danazol—Jaundice—Methimazole—Graves' disease	0.0121	0.0181	CcSEcCtD
Danazol—CCL2—pituitary gland—Graves' disease	0.0115	0.0612	CbGeAlD
Danazol—CCL2—adipose tissue—Graves' disease	0.0114	0.061	CbGeAlD
Danazol—Jaundice—Propylthiouracil—Graves' disease	0.0103	0.0154	CcSEcCtD
Danazol—CCL2—thyroid gland—Graves' disease	0.0099	0.0528	CbGeAlD
Danazol—Alopecia—Methimazole—Graves' disease	0.00981	0.0147	CcSEcCtD
Danazol—Haemoglobin—Propylthiouracil—Graves' disease	0.00949	0.0143	CcSEcCtD
Danazol—Haemorrhage—Propylthiouracil—Graves' disease	0.00944	0.0142	CcSEcCtD
Danazol—SHBG—connective tissue—Graves' disease	0.0087	0.0464	CbGeAlD
Danazol—Vertigo—Methimazole—Graves' disease	0.00868	0.013	CcSEcCtD
Danazol—Leukopenia—Methimazole—Graves' disease	0.00865	0.013	CcSEcCtD
Danazol—Alopecia—Propylthiouracil—Graves' disease	0.00834	0.0125	CcSEcCtD
Danazol—Arthralgia—Methimazole—Graves' disease	0.00823	0.0124	CcSEcCtD
Danazol—Oedema—Methimazole—Graves' disease	0.00789	0.0118	CcSEcCtD
Danazol—PGR—connective tissue—Graves' disease	0.00783	0.0418	CbGeAlD
Danazol—Thrombocytopenia—Methimazole—Graves' disease	0.00772	0.0116	CcSEcCtD
Danazol—Vertigo—Propylthiouracil—Graves' disease	0.00738	0.0111	CcSEcCtD
Danazol—Leukopenia—Propylthiouracil—Graves' disease	0.00736	0.0111	CcSEcCtD
Danazol—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00719	0.0108	CcSEcCtD
Danazol—Paraesthesia—Methimazole—Graves' disease	0.00708	0.0106	CcSEcCtD
Danazol—CYP19A1—connective tissue—Graves' disease	0.00705	0.0376	CbGeAlD
Danazol—Arthralgia—Propylthiouracil—Graves' disease	0.007	0.0105	CcSEcCtD
Danazol—Dyspepsia—Methimazole—Graves' disease	0.00694	0.0104	CcSEcCtD
Danazol—Oedema—Propylthiouracil—Graves' disease	0.00671	0.0101	CcSEcCtD
Danazol—SHBG—pituitary gland—Graves' disease	0.0067	0.0357	CbGeAlD
Danazol—CYP19A1—Metabolism of steroid hormones and vitamin D—GC—Graves' disease	0.0067	0.0457	CbGpPWpGaD
Danazol—SHBG—adipose tissue—Graves' disease	0.00667	0.0356	CbGeAlD
Danazol—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00657	0.00987	CcSEcCtD
Danazol—Urticaria—Methimazole—Graves' disease	0.00627	0.00941	CcSEcCtD
Danazol—AR—connective tissue—Graves' disease	0.00624	0.0333	CbGeAlD
Danazol—Body temperature increased—Methimazole—Graves' disease	0.00624	0.00937	CcSEcCtD
Danazol—CCL2—IL1 and megakaryotyces in obesity—ICAM1—Graves' disease	0.00615	0.0419	CbGpPWpGaD
Danazol—ESR1—connective tissue—Graves' disease	0.00613	0.0327	CbGeAlD
Danazol—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00611	0.00918	CcSEcCtD
Danazol—PGR—pituitary gland—Graves' disease	0.00604	0.0322	CbGeAlD
Danazol—Paraesthesia—Propylthiouracil—Graves' disease	0.00602	0.00905	CcSEcCtD
Danazol—PGR—adipose tissue—Graves' disease	0.00601	0.032	CbGeAlD
Danazol—Dyspepsia—Propylthiouracil—Graves' disease	0.0059	0.00887	CcSEcCtD
Danazol—SHBG—thyroid gland—Graves' disease	0.00578	0.0308	CbGeAlD
Danazol—Pruritus—Methimazole—Graves' disease	0.00558	0.00838	CcSEcCtD
Danazol—CYP19A1—adipose tissue—Graves' disease	0.00541	0.0288	CbGeAlD
Danazol—GNRHR—Peptide GPCRs—TSHR—Graves' disease	0.00533	0.0364	CbGpPWpGaD
Danazol—Urticaria—Propylthiouracil—Graves' disease	0.00533	0.008	CcSEcCtD
Danazol—Body temperature increased—Propylthiouracil—Graves' disease	0.0053	0.00797	CcSEcCtD
Danazol—PGR—thyroid gland—Graves' disease	0.0052	0.0277	CbGeAlD
Danazol—Vomiting—Methimazole—Graves' disease	0.00502	0.00753	CcSEcCtD
Danazol—Rash—Methimazole—Graves' disease	0.00497	0.00747	CcSEcCtD
Danazol—Dermatitis—Methimazole—Graves' disease	0.00497	0.00746	CcSEcCtD
Danazol—Headache—Methimazole—Graves' disease	0.00494	0.00742	CcSEcCtD
Danazol—AR—pituitary gland—Graves' disease	0.00481	0.0256	CbGeAlD
Danazol—AR—adipose tissue—Graves' disease	0.00479	0.0255	CbGeAlD
Danazol—Pruritus—Propylthiouracil—Graves' disease	0.00475	0.00713	CcSEcCtD
Danazol—ESR1—pituitary gland—Graves' disease	0.00472	0.0252	CbGeAlD
Danazol—CCL2—Chemokine receptors bind chemokines—CXCL10—Graves' disease	0.00471	0.0321	CbGpPWpGaD
Danazol—ESR1—adipose tissue—Graves' disease	0.0047	0.0251	CbGeAlD
Danazol—Nausea—Methimazole—Graves' disease	0.00469	0.00704	CcSEcCtD
Danazol—CYP19A1—thyroid gland—Graves' disease	0.00468	0.025	CbGeAlD
Danazol—CCL2—IL1 and megakaryotyces in obesity—IFNG—Graves' disease	0.00468	0.0319	CbGpPWpGaD
Danazol—Vomiting—Propylthiouracil—Graves' disease	0.00427	0.00641	CcSEcCtD
Danazol—Rash—Propylthiouracil—Graves' disease	0.00423	0.00635	CcSEcCtD
Danazol—Dermatitis—Propylthiouracil—Graves' disease	0.00423	0.00635	CcSEcCtD
Danazol—Headache—Propylthiouracil—Graves' disease	0.0042	0.00631	CcSEcCtD
Danazol—CCL2—IL1 and megakaryotyces in obesity—IL1B—Graves' disease	0.00417	0.0285	CbGpPWpGaD
Danazol—AR—thyroid gland—Graves' disease	0.00415	0.0221	CbGeAlD
Danazol—ESR1—thyroid gland—Graves' disease	0.00407	0.0217	CbGeAlD
Danazol—Nausea—Propylthiouracil—Graves' disease	0.00398	0.00598	CcSEcCtD
Danazol—CCL2—Vitamin B12 Metabolism—ICAM1—Graves' disease	0.00336	0.0229	CbGpPWpGaD
Danazol—CCL2—IL23-mediated signaling events—IFNG—Graves' disease	0.00331	0.0226	CbGpPWpGaD
Danazol—CCL2—IL23-mediated signaling events—CD4—Graves' disease	0.0032	0.0218	CbGpPWpGaD
Danazol—CCL2—AP-1 transcription factor network—HLA-A—Graves' disease	0.00298	0.0203	CbGpPWpGaD
Danazol—CCL2—IL23-mediated signaling events—IL1B—Graves' disease	0.00295	0.0201	CbGpPWpGaD
Danazol—CCL2—Folate Metabolism—ICAM1—Graves' disease	0.00274	0.0187	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—CXCL10—Graves' disease	0.00259	0.0177	CbGpPWpGaD
Danazol—PGR—Cellular roles of Anthrax toxin—IL1B—Graves' disease	0.00258	0.0176	CbGpPWpGaD
Danazol—CCL2—Vitamin B12 Metabolism—IFNG—Graves' disease	0.00256	0.0175	CbGpPWpGaD
Danazol—CCL2—Vitamin B12 Metabolism—IL1B—Graves' disease	0.00228	0.0156	CbGpPWpGaD
Danazol—CCL2—Selenium Micronutrient Network—ICAM1—Graves' disease	0.00217	0.0148	CbGpPWpGaD
Danazol—CCL2—IL-1 signaling pathway—IL1B—Graves' disease	0.00215	0.0147	CbGpPWpGaD
Danazol—CCL2—IL23-mediated signaling events—TNF—Graves' disease	0.00214	0.0146	CbGpPWpGaD
Danazol—CCL2—Folate Metabolism—IFNG—Graves' disease	0.00208	0.0142	CbGpPWpGaD
Danazol—CCL2—AP-1 transcription factor network—IFNG—Graves' disease	0.00199	0.0135	CbGpPWpGaD
Danazol—CCL2—TWEAK Signaling Pathway—TNF—Graves' disease	0.00193	0.0132	CbGpPWpGaD
Danazol—PGR—Cellular roles of Anthrax toxin—TNF—Graves' disease	0.00187	0.0128	CbGpPWpGaD
Danazol—CCL2—Folate Metabolism—IL1B—Graves' disease	0.00186	0.0127	CbGpPWpGaD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00184	0.0125	CbGpPWpGaD
Danazol—CCL2—Peptide ligand-binding receptors—CXCL10—Graves' disease	0.00177	0.0121	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—ICAM1—Graves' disease	0.00172	0.0117	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00168	0.0115	CbGpPWpGaD
Danazol—CCL2—Vitamin B12 Metabolism—TNF—Graves' disease	0.00166	0.0113	CbGpPWpGaD
Danazol—CCL2—Selenium Micronutrient Network—IFNG—Graves' disease	0.00165	0.0113	CbGpPWpGaD
Danazol—CCL2—Selenium Micronutrient Network—IL1B—Graves' disease	0.00148	0.0101	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—TSHR—Graves' disease	0.0014	0.00955	CbGpPWpGaD
Danazol—CCL2—Folate Metabolism—TNF—Graves' disease	0.00135	0.00919	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—IFNG—Graves' disease	0.00131	0.00892	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—TSHR—Graves' disease	0.00128	0.00874	CbGpPWpGaD
Danazol—CCL2—Metabolism of proteins—B3GNT2—Graves' disease	0.00119	0.00811	CbGpPWpGaD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.00119	0.00811	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—IL1B—Graves' disease	0.00117	0.00796	CbGpPWpGaD
Danazol—AR—Notch-mediated HES/HEY network—CD4—Graves' disease	0.00116	0.00791	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.00109	0.00741	CbGpPWpGaD
Danazol—CCL2—Selenium Micronutrient Network—TNF—Graves' disease	0.00107	0.0073	CbGpPWpGaD
Danazol—CCL2—TNF alpha Signaling Pathway—TNF—Graves' disease	0.00103	0.00705	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—HLA-A—Graves' disease	0.00101	0.00687	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—CXCL10—Graves' disease	0.000905	0.00617	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—TNF—Graves' disease	0.000847	0.00577	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—CXCL10—Graves' disease	0.000828	0.00565	CbGpPWpGaD
Danazol—ESR1—ATF-2 transcription factor network—IFNG—Graves' disease	0.000771	0.00526	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—TSHR—Graves' disease	0.000724	0.00494	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—TSHR—Graves' disease	0.000719	0.0049	CbGpPWpGaD
Danazol—ESR1—Regulation of Telomerase—IFNG—Graves' disease	0.000688	0.00469	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000687	0.00468	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—IFNG—Graves' disease	0.000672	0.00459	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—TSHR—Graves' disease	0.000658	0.00448	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000618	0.00422	CbGpPWpGaD
Danazol—ESR1—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000609	0.00415	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000596	0.00407	CbGpPWpGaD
Danazol—ESR1—Leptin signaling pathway—IL1B—Graves' disease	0.000568	0.00387	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000476	0.00325	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—CXCL10—Graves' disease	0.000468	0.00319	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CXCL10—Graves' disease	0.000465	0.00317	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000459	0.00313	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CXCL10—Graves' disease	0.000425	0.0029	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TSHR—Graves' disease	0.000425	0.0029	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.00041	0.0028	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TSHR—Graves' disease	0.000388	0.00265	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—IL2RA—Graves' disease	0.000358	0.00244	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—IL2RA—Graves' disease	0.000355	0.00242	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—IL2RA—Graves' disease	0.000325	0.00221	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—GC—Graves' disease	0.000306	0.00209	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000298	0.00203	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CXCL10—Graves' disease	0.000274	0.00187	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000253	0.00173	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CXCL10—Graves' disease	0.000251	0.00171	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TSHR—Graves' disease	0.000245	0.00167	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—B3GNT2—Graves' disease	0.000232	0.00158	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IL2RA—Graves' disease	0.00021	0.00143	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000195	0.00133	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IL2RA—Graves' disease	0.000192	0.00131	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CXCL10—Graves' disease	0.000158	0.00108	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TSHR—Graves' disease	0.000144	0.00098	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IL2RA—Graves' disease	0.000121	0.000825	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CXCL10—Graves' disease	9.29e-05	0.000634	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—GC—Graves' disease	8.92e-05	0.000609	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IL2RA—Graves' disease	7.1e-05	0.000484	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—B3GNT2—Graves' disease	6.76e-05	0.000461	CbGpPWpGaD
